An observational study in Cataract, Pseudoexfoliation Syndrome and Pseudophakia, sponsored by Hospital Hietzing. Completed. Open to participants aged 18 Years to 125 Years. Per ClinicalTrials.gov, last updated 2018-03-08.
Sponsored by Hospital Hietzing · Observational
To evaluate long-term intraocular lens (IOL) decentration and tilt in eyes with pseudoexfoliation syndrome (PES) following cataract surgery using Visante anterior segment OCT and iTrace Visual Function Analyzer.
64 eyes following cataract surgery from 2009 to 2012 were included, 34 eyes had PES, 30 eyes did not show PES. A standard phacoemulsification procedure followed by IOL implantation was performed and patients were followed 4-6 years after surgery (mean=69 months). Best corrected visual acuity (BCVA), intraocular pressure (IOP) and capsulorhexis size were measured. IOL tilt and IOL decentration were evaluated using Visante Omni anterior segment OCT (Carl Zeiss Jena GmBH, Germany). The iTrace VFA (Visual Function Analyzer, Topcon Medical Systems, Inc.) was used to measure internal, corneal and total optical aberrations.
Patients who underwent standard procedure cataract surgery with or without Pseudoexfoliation Syndrome.
Exclusion Criteria:
Patients after Cataract surgery with PES
Other: no intervention
Patients after Cataract surgery without PES
Other: no intervention
no intervention
IOL decentration
decentration of IOL is measured using Hoya iTrace
Time frame: 4-6 years after cataract surgery
IOL tilt
tilt of implanted IOL is measured using Hoya iTace
Time frame: 4-6 years after cataract surgery
IOL decentration
decentration of IOL is measured using Zeiss OCT
Time frame: 4-6 years after cataract surgery
IOL tilt
tilt of implanted IOL is measured using Zeiss OCT
Time frame: 4-6 years after cataract surgery
No study locations are listed for this record.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Hietzing